Notch-1 contributes to neuronal cell death and glial inflammation by modulating NFkappaB activity in ischaemic stroke (2010–2011)
Stroke is Australia's second single greatest killer after coronary heart disease and a leading cause of disability. In 2009, Australians will suffer around 60,000 new and recurrent strokes - that's one stroke every 10 minutes. There is an urgent need for novel therapies capable of reducing mortality and permanent neurological deficits in victims of stroke. We are investigating the cellular and molecular mechanisms such as Notch-1 to develop therapeutic targets to treat stroke injury.